Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Trial Profile

An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deutetrabenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RIM-TD
  • Sponsors Auspex Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2022 Results of a post hoc analysis of OLE study assessed long-term efficacy and safety of DTBZ in postmenopausal women presented at the 175th Annual Meeting of the American Psychiatric Association
    • 26 Apr 2022 Results of post hoc analysis assessing dosing patterns by severity of tardive dyskinesia (TD) according to baseline Abnormal Involuntary Movement Scale (AIMS) item 8 score presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 26 Apr 2022 Results of post hoc analysis assessing long term safety and efficacy presented at the 74th Annual Meeting of the American Academy of Neurology 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top